5 January 2023
Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, is pleased to announce that the U.S. Food and Drug Administration (“FDA”) has granted Qualified Infectious Disease Product (“QIDP”) designation to MET-X, the...
15 December 2022
Diabetes self-management app intellin® is a cost-effective solution for preventing diabetic foot ulcer recurrence
A study published in the journal Digital Health has found that the intellin® mHealth diabetes management platform is a cost-effective solution for managing and preventing the recurrence of diabetic foot ulcers. The study assessed patients at Salford Royal NHS Foundation...
14 December 2022
Pill Connect dispenser supports clinical trial for personalised Tuberculosis care
Pill Connect the smart dosing technology provider, has today announced the completion of its first clinical trial in collaboration with the UMCG KFF Clinical Pharmacy and Pharmacology in the Netherlands. Utilising Pill Connect’s Smart Dispenser technology, the study aimed...
29 November 2022
Extra £6.5m secured by tech firm which uses AI to speed up scientific discovery as it eyes US expansion
A tech spin-out from the University of Manchester, which uses AI to curate masses of biomedical data to help scientists speed up research and development, has secured a £6.5m boost. Biorelate has completed a Series A investment round led by Maven Capital Partners and YFM...
23 November 2022
Blueberry Therapeutics Ltd announces nomination of BB1511 for clinical development for the treatment of Atopic Dermatitis (Eczema)
Alderley Park, 22 November 2022 – Blueberry Therapeutics are pleased to announce that their novel cream formulation for the treatment of atopic dermatitis (BB1511) has been nominated for clinical development. This nomination decision was unanimous following review of...
21 November 2022
Infex enters clinic with lead anti-virulence candidate RESP-X for Pseudomonas aeruginosa
Infex Therapeutics, a leading anti-infectives specialist, is pleased to announce the first subjects have been dosed in Phase I study in healthy volunteers evaluating the Company's lead drug candidate RESP-X, a new anti-virulence therapy to treat Pseudomonas aeruginosa (Pa)...
9 November 2022
Biorelate and Copyright Clearance Centre announce strategic integration
Manchester, UK. Biorelate Limited (“Biorelate”) and CCC (Copyright Clearance Center), have announced a strategic integration. Biorelate’s customers will immediately have the option to access subscription-only scholarly article content in XML format licensed...
8 November 2022
First Choice Neurology partners with Cytox
November 7, 2022 – First Choice Neurology (FCN), the largest neurology group in the U.S. with more than 41 facilities in six Florida counties and services at 35 major hospitals, has partnered with U.K-based Cytox to become the first practice in the United States to offer...
3 October 2022
Oxford BioTherapeutics enters into Commercial License Agreement with Genmab
• OBT licenses to Genmab the rights to a novel, pre-clinical first-in-class immuno-oncology (IO) antibody. • Under its Commercial License Agreement with OBT, Genmab will obtain the exclusive right to develop and commercialize novel antibody therapeutics utilizing...
28 September 2022
“Gift of time” could enable nearly 100 more kidney transplants each year
• Kidney Research UK says that a new method of preserving donated kidneys could offer hope and the “gift of time” to save kidneys from being discarded … • The charity reveals that nearly 100 kidneys a year are not transplanted after retrieval as they are deemed...